Your session is about to expire
← Back to Search
Synapse 3D + IC-Green for Early-Stage Lung Cancer
Study Summary
This trial will study a new surgical technique to facilitate minimally invasive pulmonary segmentectomy, which may provide advantages over lobectomy for patients with early-stage lung cancer or comorbidities.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My CT scan shows my lung tumor is small enough for a specific type of surgery.I am not pregnant, breastfeeding, and if able to bear children, I am using effective birth control.My condition is early-stage non-small cell lung cancer.My scans show cancer has spread to nearby lymph nodes.You are allergic to ICG, sodium iodide, or iodine.My tumor is smaller than 3 cm.Your lung function tests show that you have very low breathing capacity.
- Group 1: Synapse 3D Lung Modelling + IC-GREEN Segmentectomy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any open slots remaining for participants in this research trial?
"Unfortunatley this trial has concluded its recruitment process. It began on January 1st 2023 and was last updated November 2nd 2022, so it is no longer open to enrollment. Fortunately there are still 1576 trials actively recruiting patients with non-small cell lung cancer and 30 studies that require VisiblePatient™ 3D Lung Modelling participants."
What are the primary objectives of this research endeavor?
"This medical trial seeks to measure the Segmental Resection Conversion Rate over a one year period as its primary outcome. Secondary outcomes being considered include Length of Stay, Anatomical Accuracy of the 3D Lung Model, and Surgeon Confidence. The latter is rated on a scale from 1-5: 'not at all confident' to 'extremely confident'."
How many participants are currently involved in this medical research?
"At present, this study is not enrolling candidates. The research project was initially posted on January 1st 2023 and its last update occurred on November 2nd 2022. If you are investigating other studies, there are currently 30 trials for VisiblePatient™ 3D Lung Modelling recruiting participants as well as 1576 medical experiments involving those with non-small cell lung cancer in search of volunteers."
Share this study with friends
Copy Link
Messenger